SIBN FINANCIAL STATEMENTS

Si-Bone Inc — balance sheet, income statement and cash flow trends

SIBNSi-Bone Inc

🇺🇸 USA · NASDAQ · Healthcare · Medical Devices

Value it Duel

Income Statement

Quarterly progression — trailing-twelve-month values

RevenueNet Income

Profit Funnel

Q1 2026 · TTM

Percentages are relative to revenue.

Key Figures

YoY change

Revenue206.2 M $+16.8%

Gross Profit164.1 M $+17.3%

Operating Income-19.9 M $—

EBITDA-6 M $—

Net Income-16.7 M $—

Peer Comparison· Medical Devices

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
SIBN	16.8%	79.6%	-2.9%	-8.1%
4DX	-26.0%	-396.6%	-818.8%	-3,684.6%
SN	—	68.0%	25.6%	10.1%
ONCSM	39.1%	48.4%	30.6%	6.3%
COH	2.0%	73.0%	24.0%	14.6%
MEDTR	6.5%	30.9%	9.4%	0.2%
Industry median	7.4%	58.9%	5.2%	-5.7%

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
SIBN	16.8%	79.6%	-2.9%	-8.1%
TCMD	17.2%	75.7%	12.1%	5.9%
CERS	20.3%	54.3%	0.5%	-4.3%
INMD	-4.5%	77.8%	27.5%	23.3%
CTKB	3.6%	51.7%	-10.8%	-36.2%
CLPT	26.0%	61.8%	-58.2%	-71.6%
Industry median	7.4%	58.9%	5.2%	-5.7%

Balance Sheet

Quarterly period-end values

Total AssetsTotal LiabilitiesEquity

Capital Structure

Q1 2026

Equity178.9 M $74%
Current Liabilities21.5 M $9%
Long-term Liabilities42.3 M $17%

Key Figures

YoY change

Total Assets242.7 M $+6.8%

Total Liabilities63.8 M $+6.3%

Total Equity178.9 M $+7.0%

Cash & ST Investments144.7 M $+0.2%

Total Debt7.3 M $-80.2%

Net Debt-26.2 M $—

Peer Comparison· Medical Devices

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
SIBN	9.99	4.1%	22.93	73.7%
4DX	6.57	-22.6%	0.71	-20.4%
SN	2.57	62.9%	1.72	50.6%
ONCSM	2.25	35.0%	0.42	56.4%
COH	2.46	22.1%	0.42	69.4%
MEDTR	3.58	1.0%	-1.64	83.0%
Industry median	3.28	44.7%	0.82	49.7%

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
SIBN	9.99	4.1%	22.93	73.7%
TCMD	4.24	7.0%	-1.44	80.1%
CERS	1.63	144.1%	14.23	30.3%
INMD	8.80	0.7%	-5.17	88.1%
CTKB	4.69	11.1%	10.20	73.0%
CLPT	5.79	337.5%	-1.18	20.2%
Industry median	3.28	44.7%	0.82	49.7%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values

Operating Cash FlowCapital ExpendituresFree Cash Flow

Cash Flow Bridge

Q1 2026 · TTM

Key Figures

YoY change

Operating Cash Flow1.9 M $—

Capital Expenditures7.4 M $-29.3%

Free Cash Flow-5.5 M $—

Dividends Paid——

Peer Comparison· Medical Devices

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
SIBN	0.9%	-2.7%	3.6%	-11.2%
4DX	-761.6%	-530.7%	3.7%	20.7%
SN	20.8%	13.8%	7.0%	205.6%
ONCSM	6.2%	-5.5%	12.0%	99.3%
COH	11.2%	8.5%	2.7%	76.6%
MEDTR	21.1%	27.9%	6.6%	10,700.8%
Industry median	7.2%	1.5%	4.1%	76.6%

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
SIBN	0.9%	-2.7%	3.6%	-11.2%
TCMD	12.2%	11.4%	0.9%	207.2%
CERS	1.2%	-0.5%	1.7%	-27.6%
INMD	24.5%	24.2%	0.3%	105.2%
CTKB	-3.6%	-6.2%	2.6%	9.9%
CLPT	-63.3%	-65.8%	2.4%	88.5%
Industry median	7.2%	1.5%	4.1%	76.6%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on SIBN

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 6, 26. This content is for informational purposes only and is not investment advice.